Lucas Dato Ana, Wikman-Jorgensen Philip, Saugar Cruz José María, García-Vázquez Elisa, Llenas-García Jara
Internal Medicine/Infectious Diseases Department, Vega Baja Hospital-Orihuela, 03314 Alicante, Spain.
Foundation for the Promotion of Health and Biomedical Research of the Valencia Region (FISABIO), 46020 Valencia, Spain.
Trop Med Infect Dis. 2025 Apr 1;10(4):91. doi: 10.3390/tropicalmed10040091.
Strongyloidiasis, caused by the soil-transmitted helminth , is estimated to infect around 600 million people worldwide. Ivermectin is the current first-line treatment. This prospective study evaluated long-term treatment response in patients with chronic strongyloidiasis. Conducted from 2019 to 2022 at Vega Baja Hospital in Alicante, Spain, this study enrolled 28 patients diagnosed with infection. Patients received ivermectin at a dosage of 200 mcg/kg for one or two days and were followed for at least 12 months, with evaluations at 3, 6, 12, and 18 months post-treatment. Assessments included hemogram, IgE, serology, larvae culture and direct visualization and PCR in stool. Twenty-three patients completed at least 12 months of follow-up. Twenty-one patients (91.3%) achieved treatment response. Two patients (8.6%) experienced parasitological treatment failure, with detectable DNA during follow-up. Ivermectin is highly effective in treating strongyloidiasis, with serology aiding in monitoring treatment efficacy. However, PCR detected an additional case of persistent infection, underscoring its complementary role.
由土源性蠕虫引起的类圆线虫病估计在全球感染约6亿人。伊维菌素是目前的一线治疗药物。这项前瞻性研究评估了慢性类圆线虫病患者的长期治疗反应。该研究于2019年至2022年在西班牙阿利坎特的贝加下城医院进行,纳入了28例确诊感染的患者。患者接受剂量为200 mcg/kg的伊维菌素治疗1或2天,并至少随访12个月,在治疗后3、6、12和18个月进行评估。评估包括血常规、IgE、血清学、幼虫培养、粪便直接镜检和PCR。23例患者完成了至少12个月的随访。21例患者(91.3%)获得治疗反应。2例患者(8.6%)出现寄生虫学治疗失败,随访期间可检测到DNA。伊维菌素治疗类圆线虫病非常有效,血清学有助于监测治疗效果。然而,PCR检测到另外1例持续感染病例,突出了其辅助作用。